ImageneBio Inc (IMA) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.20
↓-98% vs avg
5yr avg: 9.50
30Y Low0.3·High26.0
ROE
↑
-35.0%
↓+15% vs avg
5yr avg: -41.1%
30Y Low-64%·High-25%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
IMA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
ImageneBio Inc currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $61M | $34M | $950M | $987M | $1.2B | $5.4B | — | — | — |
| Enterprise Value | $36M | $9M | $918M | $877M | $1.1B | $5.2B | — | — | — |
| P/E Ratio → | -0.50 | — | — | — | — | — | — | — | — |
| P/S Ratio | 76.54 | 42.01 | 271.35 | 107.71 | 73.96 | 174.71 | — | — | — |
| P/B Ratio | 0.20 | 0.25 | 7.54 | 5.81 | 7.86 | 26.04 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
IMA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 10.80 | 262.24 | 95.79 | 70.49 | 167.45 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
IMA Profitability
Margins and return-on-capital ratios measuring operating efficiency
ImageneBio Inc earns an operating margin of -6056.4%. Operating margins have compressed from -823.3% to -6056.4% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -35.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -29.1% | -29.1% | 100.0% | 88.9% | -311.8% | -52.0% | -387.8% | -81.3% | -3838.0% |
| Operating Margin | -6056.4% | -6056.4% | -1057.1% | -823.3% | -454.0% | -110.2% | -484.2% | -134.5% | -4130.7% |
| Net Profit Margin | -5668.6% | -5668.6% | -1044.8% | -744.2% | -440.3% | -110.1% | -481.4% | -122.3% | -4127.8% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -35.0% | -35.0% | -24.7% | -43.0% | -38.8% | -63.9% | — | — | — |
| ROA | -30.8% | -30.8% | -21.9% | -37.4% | -32.7% | -16.4% | -34.8% | -31.5% | -197.6% |
| ROIC | -35.9% | -35.9% | -35.9% | -73.8% | -141.1% | — | — | — | — |
| ROCE | -35.6% | -35.6% | -24.0% | -45.9% | -38.2% | -18.9% | -44.1% | -47.1% | -242.7% |
IMA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $35M exceeds total debt of $10M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.08 | 0.08 | 0.06 | 0.06 | 0.04 | 0.03 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.19 | -0.25 | -0.64 | -0.37 | -1.08 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | -1.72 | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($35M) exceeds total debt ($10M)
IMA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
ImageneBio Inc's current ratio of 12.49x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 12.58x to 12.49x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.49 | 12.49 | 11.80 | 12.58 | 7.44 | 8.70 | 5.86 | 3.51 | 5.22 |
| Quick Ratio | 12.49 | 12.49 | 11.80 | 12.58 | 7.44 | 8.70 | 5.86 | 3.51 | 5.22 |
| Cash Ratio | 6.75 | 6.75 | 11.54 | 12.35 | 7.30 | 8.54 | 5.74 | 3.38 | 4.75 |
| Asset Turnover | — | 0.01 | 0.02 | 0.05 | 0.09 | 0.13 | 0.05 | 0.16 | 0.05 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 591.30 | — | — | — | — | — | — | — |
IMA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
ImageneBio Inc does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $5M | $48M | $42M | $36M | $36M | $14M | $36M | $36M |
Peer Comparison
Compare IMA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 IMAYou | $61M | -0.5 | — | — | -29.1% | -6056.4% | -35.0% | -35.9% | — |
 SRZN | $175M | -0.7 | — | — | 84.6% | -1210.6% | — | — | — |
 IMVT | $7B | -12.1 | — | — | — | — | -64.8% | — | — |
 KYMR | $7B | -23.4 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 ARQT | $3B | -187.5 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 PRTA | $432M | -1.8 | — | — | 61.8% | -1905.8% | -63.6% | -2099.8% | — |
 ALNY | $38B | 121.4 | 67.0 | 81.1 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 RARE | $2B | -4.2 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 ACAD | $4B | 9.2 | 25.1 | 34.3 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 PTCT | $6B | 9.7 | 6.4 | 8.9 | 95.9% | 49.5% | — | — | 0.5 |
| Healthcare Median | — | 22.9 | 14.4 | 18.9 | 63.9% | -4.3% | -32.6% | -11.4% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
What if you invested $1,000 in IMA 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in IMA be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs IMA Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationIMA vs SRZN — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Surrozen, Inc..
Compare NowIMA — Frequently Asked Questions
Quick answers to the most common questions about buying IMA stock.
What is ImageneBio Inc's P/E ratio?
ImageneBio Inc's current P/E ratio is -0.5x. This places it at the 50th percentile of its historical range.
What is ImageneBio Inc's ROE?
ImageneBio Inc's return on equity (ROE) is -35.0%. The historical average is -41.1%.
Is IMA stock overvalued?
Based on historical data, ImageneBio Inc is trading at a P/E of -0.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are ImageneBio Inc's profit margins?
ImageneBio Inc has -29.1% gross margin and -6056.4% operating margin.